Nuvectis Pharma (NVCT) Revenue & Revenue Breakdown
Nuvectis Pharma Revenue Highlights
00
Nuvectis Pharma Revenue by Period
Nuvectis Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $149.00K | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
Nuvectis Pharma generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Nuvectis Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $26.80M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $-4.10M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $4.10M | 2652.35% |
| 2022-12-31 | $149.00K | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $4.00K | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | - |
Nuvectis Pharma generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Nuvectis Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IPHA | Innate Pharma | $51.90M | $16.56M |
| CGEN | Compugen | $33.46M | $2.56M |
| TNXP | Tonix Pharmaceuticals | $10.09M | $3.29M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| NVCT | Nuvectis Pharma | - | - |
| SAVA | Cassava Sciences | - | $840.00K |
| RANI | Rani Therapeutics | - | - |
| CRDF | Cardiff Oncology | - | $121.00K |
| MIST | Milestone Pharmaceuticals | - | - |